Search Results - "Holz, Marina K"

Refine Results
  1. 1

    The therapeutic potential of resveratrol: a review of clinical trials by Berman, Adi Y., Motechin, Rachel A., Wiesenfeld, Maia Y., Holz, Marina K.

    Published in NPJ precision oncology (25-09-2017)
    “…Resveratrol is a nutraceutical with several therapeutic effects. It has been shown to mimic effects of caloric restriction, exert anti-inflammatory and…”
    Get full text
    Journal Article
  2. 2

    Unraveling the multifaceted nature of the nuclear function of mTOR by Torres, Alek S, Holz, Marina K

    “…Positioned at the axis between the cell and its environment, mTOR directs a wide range of cellular activity in response to nutrients, growth factors, and…”
    Get more information
    Journal Article
  3. 3

    The role of S6K1 in ER-positive breast cancer by Holz, Marina K.

    Published in Cell cycle (Georgetown, Tex.) (01-09-2012)
    “…The 40S ribosomal S6 kinase 1 (S6K1) is a conserved serine/threonine protein kinase that belongs to the AGC family of protein kinases, which also includes Akt…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Identification of S6 Kinase 1 as a Novel Mammalian Target of Rapamycin (mTOR)-phosphorylating Kinase by Holz, Marina K., Blenis, John

    Published in The Journal of biological chemistry (15-07-2005)
    “…Here we demonstrate that mammalian target of rapamycin (mTOR) is phosphorylated in a rapamycin-sensitive manner. We show that S6 kinase 1 (S6K1), but not Akt,…”
    Get full text
    Journal Article
  6. 6

    RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation by Roux, Philippe P., Shahbazian, David, Vu, Hieu, Holz, Marina K., Cohen, Michael S., Taunton, Jack, Sonenberg, Nahum, Blenis, John

    Published in The Journal of biological chemistry (11-05-2007)
    “…Converging signals from the mammalian target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) pathways are well established to modulate translation…”
    Get full text
    Journal Article
  7. 7

    mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events by Holz, Marina K., Ballif, Bryan A., Gygi, Steven P., Blenis, John

    Published in Cell (18-11-2005)
    “…In response to nutrients, energy sufficiency, hormones, and mitogenic agents, S6K1 phosphorylates several targets linked to translation. However, the molecular…”
    Get full text
    Journal Article
  8. 8

    Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer by Alayev, Anya, Salamon, Rachel S., Schwartz, Naomi S., Berman, Adi Y., Wiener, Sara L., Holz, Marina K.

    Published in Journal of cellular physiology (01-02-2017)
    “…Loss of TSC1 function, a crucial negative regulator of mTOR signaling, is a common alteration in bladder cancer. Mutations in other members of the PI3K…”
    Get full text
    Journal Article
  9. 9

    Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors by Alayev, Anya, Salamon, Rachel S, Sun, Yang, Schwartz, Naomi S, Li, Chenggang, Yu, Jane J, Holz, Marina K

    “…Lymphangioleiomyomatosis (LAM) is a rare neoplastic metastatic disease affecting women of childbearing age. LAM is caused by hyperactivation of the mechanistic…”
    Get full text
    Journal Article
  10. 10

    mTOR signaling for biological control and cancer by Alayev, Anya, Holz, Marina K.

    Published in Journal of cellular physiology (01-08-2013)
    “…Mammalian target of rapamycin (mTOR) is a major intersection that connects signals from the extracellular milieu to corresponding changes in intracellular…”
    Get full text
    Journal Article
  11. 11

    Lymphangioleiomyomatosis: a metastatic lung disease by Kundu, Nandini, Holz, Marina K

    “…Lymphangioleiomyomatosis (LAM) is a rare disease affecting women, caused by somatic mutations in the TSC1 or TSC2 genes, and driven by estrogen. Similar to…”
    Get more information
    Journal Article
  12. 12

    RSK as a Therapeutic Target for ER+ Breast Cancer by Faltas, Christina, Holz, Marina K.

    Published in The FASEB journal (01-05-2022)
    “…We focus on identification of kinase signaling pathways, inhibition of which could be used in combination with endocrine therapy for treatment of Estrogen…”
    Get full text
    Journal Article
  13. 13

    Unconventional Estrogen Signaling in Health and Disease by Faltas, Christina L, LeBron, Kira A, Holz, Marina K

    Published in Endocrinology (Philadelphia) (01-04-2020)
    “…Abstract Estrogen is a key hormone involved in the development and homeostasis of several tissue types in both males and females. By binding estrogen…”
    Get full text
    Journal Article
  14. 14

    Regulation of mRNA translation by estrogen receptor in breast cancer by Fard, Shahrzad S., Holz, Marina K.

    Published in Steroids (01-12-2023)
    “…•Translational dysregulation in cancer leads to the synthesis of factors promoting tumorigenesis and drug resistance.•Key regulators include eIFs, PABP, and…”
    Get full text
    Journal Article
  15. 15

    Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f) by Cuesta, Rafael, Berman, Adi Y., Alayev, Anya, Holz, Marina K.

    Published in The Journal of biological chemistry (15-02-2019)
    “…Approximately two thirds of all breast cancer cases are estrogen receptor (ER)–positive. The treatment of this breast cancer subtype with endocrine therapies…”
    Get full text
    Journal Article
  16. 16

    Fanconi anemia and mTOR pathways functionally interact during stalled replication fork recovery by Nolan, Matthew, Knudson, Kenneth, Holz, Marina K., Chaudhury, Indrajit

    Published in FEBS letters (01-03-2021)
    “…We have previously demonstrated that Fanconi anemia (FA) proteins work in concert with other FA and non‐FA proteins to mediate stalled replication fork…”
    Get full text
    Journal Article
  17. 17

    The Combination of Rapamycin and Resveratrol Blocks Autophagy and Induces Apoptosis in Breast Cancer Cells by Alayev, Anya, Berger, Sara Malka, Kramer, Melissa Y., Schwartz, Naomi S., Holz, Marina K.

    Published in Journal of cellular biochemistry (01-03-2015)
    “…ABSTRACT Hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) is a frequent event in breast cancer and current efforts are aimed at…”
    Get full text
    Journal Article
  18. 18

    mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation by Yamnik, Rachel L., Holz, Marina K.

    Published in FEBS letters (04-01-2010)
    “…Resistance to anti-estrogen therapy is a major clinical concern in treatment of breast cancer. Estrogen-independent phosphorylation of estrogen receptor α,…”
    Get full text
    Journal Article
  19. 19

    Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation by Alayev, Anya, Berger, Sara Malka, Holz, Marina K.

    Published in Annals of the New York Academy of Sciences (01-08-2015)
    “…The mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway is hyperactivated in a variety of cancers and tumor syndromes. Therefore, mTORC1…”
    Get full text
    Journal Article
  20. 20

    RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer by Cuesta, Rafael, Holz, Marina K

    Published in Oncotarget (10-05-2016)
    “…The p90 ribosomal S6 kinase (RSK) is a family of MAPK-activated serine/threonine kinases (RSK1-4) whose expression and/or activity are deregulated in several…”
    Get full text
    Journal Article